Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib Dose-Escalation Study of Tiragolumab Alone and With Atezolizumab in Advanced Solid Tumors (Japan)
jRCT2031210432Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tiragolumab in Non-hematologic malignancy (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of adverse events and 3 more. Started Mar 2022; status: completed.
02
Drugs
tiragolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031210432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210432.